Clinical data | |
---|---|
Pronunciation | /ˌsaɪkloʊˈfɒsfəˌmaɪd, -lə-/[1][2] |
Trade names | Lyophilized Cytoxan, Endoxan, Cytoxan, Neosar, Procytox, Revimmune, Cycloblastin |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682080 |
Pregnancy category |
|
Routes of administration | By mouth, by injection into a vein |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | >75% (by mouth) |
Protein binding | >60% |
Metabolism | Liver |
Elimination half-life | 3–12 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.015 |
Chemical and physical data | |
Formula | C7H15Cl2N2O2P |
Molar mass | 261.08 g·mol−1 |
3D model (JSmol) | |
Melting point | 2 °C (36 °F) |
| |
| |
(verify) |
Cyclophosphamide (CP), also known as cytophosphane among other names,[3] is a medication used as chemotherapy and to suppress the immune system.[4] As chemotherapy it is used to treat lymphoma, multiple myeloma, leukemia, ovarian cancer, breast cancer, small cell lung cancer, neuroblastoma, and sarcoma.[4] As an immune suppressor it is used in nephrotic syndrome, granulomatosis with polyangiitis, and following organ transplant, among other conditions.[4][5] It is taken by mouth or injection into a vein.[4]
Most people develop side effects.[4] Common side effects include low white blood cell counts, loss of appetite, vomiting, hair loss, and bleeding from the bladder.[4] Other severe side effects include an increased future risk of cancer, infertility, allergic reactions, and pulmonary fibrosis.[4] Cyclophosphamide is in the alkylating agent and nitrogen mustard family of medications.[4] It is believed to work by interfering with the duplication of DNA and the creation of RNA.[4]
Cyclophosphamide was approved for medical use in the United States in 1959.[4] It is on the World Health Organization's List of Essential Medicines.[6]